STAAR Surgical Co.

STAAR Surgical Co.

STAAR Surgical Co.

Overview
Date Founded

1986

Headquarters

1911 WALKER AVENUE, MONROVIA, CA, 91016

Type of Company

Public

Employees (Worldwide)

475

Industries

Medical Products & Equipment
Industrial Machinery & Manufacturing
Hospitals & Patient Services

Company Description

STAAR Surgical Company is at the vanguard of minimally invasive ophthalmic vision enhancement and technology. We believe in the importance of improving the efficiency, convenience, and comfort of corrective eye surgery for both medical professionals and patients. It is for this reason that we continually evaluate our existing products to ensure that we are providing the latest cataract, refractive error, and glaucoma treatments. From our patented COLLAMER lenses to Cruise Control, our unique new high vacuum surgery system, STAAR Surgical Company is responsible for some of the most revolutionary developments in ophthalmology. Regarded as a technology leader in the surgical eye correction industry, STAAR Surgical Company was founded in 1982 when the intraocular lens (IOL) was still in its relative infancy. Although still an integral part of the company's portfolio, STAAR Surgical Company's product lines have expanded beyond cataract correction solutions to include lenses and medical devices for refractive and glaucoma surgery. STAAR Surgical Company has revolutionized the industry with its development and use of Collamer. This unique lens material is used in the Afinity™ line of intraocular lenses (IOLs), the Visian ICL, and the Visian TICL*. Each Collamer lens produced by STAAR Surgical Company is made from a material that not only is durable, but also replicates features of the eye's natural lens, creating high quality of vision and optimal biocompatibility. STAAR Surgical Company has developed into a global surgical eye correction technology leader. To foster ongoing growth, we emphasize creativity, research, and development. Using these tools, STAAR Surgical Company plans to continue making advancements in technology, marketing, and financial strength

Contact Data
Trying to get in touch with decision makers at STAAR Surgical Co.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Vice President, Chief Financial Officer & Principal Accounting Officer

Chief Technology Officer

Chief Medical Officer

Global Head of Regulatory Affairs & Quality Assurance

President, International Commercial Operations

Senior Vice President, Commercial Operations North America & APAC

Senior Vice President-Global Operations

Vice President, Global Clinical & Medical Affairs

Vice President, Global Human Resources

Board of Directors

Chairman & Chief Executive Officer at Advanced ICU Care, Inc.

President & Chief Executive Officer at STAAR Surgical Co.

Chief Executive Officer at Convey Health Solutions, Inc.

Former Fund Advisor at Abrams Capital Management LP

Chief Technology Officer at TearSolutions, Inc.

Paths to STAAR Surgical Co.
Potential Connections via
Relationship Science
You
STAAR Surgical Co.
Owners & Shareholders
Details Hidden

Broadwood Capital conducts in-depth fundamental research to make investment decisions andrecommendations. The firm's research includes analysis of \"micro\" variables such as company,industry, and sector specific business drivers, as well as \"macro\" considerations such as global economic growth drivers, monetary and fiscal policies, and geopolitical developments. They employ the following strategies: Buy and Hold; Diversification; Fundamental Value; Hedging; Leverage; Low Portfolio Turnover; Shareholder Activism; Short Selling; and Tax Efficiency.

Details Hidden

Palo Alto Investors, LLC (PAI) is a leading private investment firm. We make long-term investments for high-net-worth and institutional investors based on original, deep, fundamental research. We don’t rent stocks. We own them. With approximately $900 million in assets under management, we offer a diversified micro cap fund and healthcare sector funds. Significant partner ownership in all of our Funds serves to align our financial interests with the financial interests of our clients. At PAI our mission is to deliver superior returns to our clients by investing for the long term. At the core of our investment philosophy lies the belief that intensive, original research is required to discover and evaluate inefficiently priced equities. We generally focus our investments in micro cap and small cap U.S. equities, which are not closely followed by Wall Street sell-side research firms. We target overlooked, misunderstood and undervalued segments of the equity markets, such as healthcare, energy and technology that have significant potential for appreciation. Our experienced research team has extensive industry experience in the sectors they cover. They utilize a disciplined, bottom-up approach to identify promising investments, and the firm’s investment policies ensure liquidity horizons that are sufficient to take advantage of new opportunities. PAI is committed to providing exemplary client service, maintaining the highest level of ethics, operational excellence and professionalism. PAI is independently owned, and has been registered with the SEC since its inception in 1989

Details Hidden

Geneva Capital Management (GCM) specializes in making growth stock investments in US companies and offer five styles of growth-stock investing: Small-Cap, Small/Mid-Cap, Mid-Cap, Large-Cap and All-Cap. They select investments based primarily on fundamental analysis, rather than market timing. GCM also offers investments in taxable and tax-exempt fixed income securities. For fixed income investments, they use corporate bonds, municipal bonds, government securities and bank certificates of deposit. GCM may use other types of fixed-income securities based on the needs and objectives of particular clients. The firm also provides their model portfolio to a small number of financial firms.For equity securities, GCM employs fundamental analysis to identify high quality companies with superior management teams, leadership positions in their industries, low debt, and consistent earnings growth. GCM believes that investing in proven, high quality companies can lead to superior returns with below average risk over the market cycle. They generally do not invest in IPOs, companies with headquarters outside the US whose management teams do not operate in the US and whose equity securities do not trade on a US exchange, highly leveraged companies, or turnaround situations. GCM generally purchases stocks with the intent of holding them for long periods of time.For fixed income securities, GCM engages in fundamental fixed income analysis to identify high quality debt issuers with superior management teams, low leverage and consistent earnings. In addition, they apply traditional credit analysis to assess the capacity, collateral and character of each issue. GCM generally purchases fixed income securities with the intent of holding the investments until maturity.

Recent Transactions
Details Hidden

STAAR Surgical Co. issued . USD Common Stock

Details Hidden

BPE Unternehmensbeteiligungen GmbH, Domilens Beteiligungs GmbH purchase Domilens GmbH from STAAR Surgical Co.

Details Hidden

STAAR Surgical Co. purchases Canon STAAR Co., Inc. from Canon, Inc. resulting in a new company STAAR Japan, Inc.

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onSTAAR Surgical Co. issued . USD Common Stock

Escrow Agent

Advised onSTAAR Surgical Co. issued . USD Common Stock

Selling Group Member

Advised onSTAAR Surgical Co. issued . USD Common Stock

Senior Managing Director

Advised onSTAAR Surgical Co. issued . USD Common Stock

Legal Advisor

Advised onSTAAR Surgical Co. issued . USD Common Stock

Advisors & Consultants
Consultant

Former President & Chief Executive Officer at STAAR Surgical Co.

Key Stats and Financials As of 2018
Market Capitalization
$1.6B
Total Enterprise Value
$1.32B
Earnings Per Share
$0.11
Revenue
$124M
Net Profit
$4.97M
EBITDA
$9.06M
EBITDAMargin
7.31%
TEVNet Income
264.93x
Debt TEV
0x
Enterprise Value Sales
10.62x
Total Debt
$5.34M
Total Equity
$132M
Enterprise Value EBITDAOperating
145.29x
Five Year Compounded Annual Growth Rate Of Revenue
11.41%
Three Year Compounded Annual Growth Rate Of Revenue
17.14%
Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Bausch Health Cos., Inc. Pharmaceuticals - Laval, QC

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Alcon, Inc. Medical Products & Equipment

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through Surgical and Vision Care segments. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Hünenberg, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by STAAR Surgical Co.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of STAAR Surgical Co.'s profile does not indicate a business or promotional relationship of any kind between RelSci and STAAR Surgical Co..